<DOC>
	<DOCNO>NCT02358304</DOCNO>
	<brief_summary>The main objective randomise clinical trial compare frequency recurrence patient receive nasal spray calcitonin curettage Central Giant Cell Granuloma without .</brief_summary>
	<brief_title>Efficacy Nasal Spray Calcitonin Recurrence Aggressive Central Giant Cell Granuloma</brief_title>
	<detailed_description>A total 24 patient aggressive Central Giant Cell Granuloma ( CGCG ) select . All examination perform calibrated clinician gender , age , medical history , symptom , lesion size site , disease duration form treatment record participant . Radiographic examination cone beam compute tomography ( CBCT ) panoramic radiograph do patient . All patient randomly assign one two treatment group ; 2 week biopsies take . The case group ( n =12 ) underwent 200 IU/day one day 3 month surgery . conservative curettage surgical procedure do . placebo treat curettage CGCGs receive placebo one day 3 month surgeries.. Patients follow maxillofacial surgeon participate surgeries.None surgeon aware research operations.Patients blind drug receive surgery . All patient follow 5 year operation . Recurrence lesion document clinical radiographical examination prove histopathological evaluation .</detailed_description>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>Granuloma , Giant Cell</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>clinical histopathological diagnosis aggressive CGCG base accept criterion establish chuong etal normal level calcitonin serum Parathyroid hormone ( PTH ) Patients sex 13 30 year 's old Patients give write informed consent Patients willing evaluation fallow session Primary size lesion 5 cm CBCT Participants demonstrate systemic disease affect bone healing , brown tumor , pregnancy , recently corticosteroid therapy , previous surgical intervention CGCG refuse study enrollment could continue study private social reason exclude study sample .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>